Crusade Laboratories Limited

Virttu Biologics Limited

The Wistar Institute

University of Glasgow

Other

Sloan-kettering Institute for Cancer Research

Medical Research Council

Susanne Moira Brown

Joe Conner

Alasdair Roderick MacLean

Nigel William Fraser

Paul Dunn

Bruce Paul Randazzo

June Harland

Alasdair R Maclean

Bhuvanesh Singh

Ian Ganly

Guy Michael Gary Hamilton

A herpes simplex virus is disclosed in which the herpes simplex virus genome comprises a nucleic acid sequence encoding an ING4 polypeptide.

Herpes simplex viruses and methods of viral replication

There is provided an HSV complex which comprises an avirulent HSV and a targeting agent which allows the HSV particle to infect and lyse a specific targeted cell. The inventors have found a way in which avirulent HSV can be targeted to disease cells, e.g. cancer cells, by incorporating an antibody binding domain into one or more viral glycoproteins.

Herpes simplex virus complex

An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding an antisense to the squamous cell carcinoma related oncogene (asSCCRO); and an herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a short interfering ribonucleic acid (siRNA) molecule that is capable of repressing or silencing expression of squamous cell carcinoma related oncogene (SCCRO) nucleic acid or polypeptide are disclosed together with methods for generation and applications of such viruses.

Methods for treating cancer using herpes simplex virus expressing antisense to the squamous cell carcinoma related oncogene

Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the &#x3b3;34.5 gene in the long repeat region (R) such that the &#x3b3;34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.

Treatment of melanoma using HSV mutant

There is provided an HSV Complex which comprises an avirulent HSV and a targeting agent which allows the HSV particle to infect and lyse a specific targeted cell. The inventors have found a way in which avirulent HSV can be targeted to disease cells, e.g. cancer cells, by incorporating an antibody binding domain into one or more viral glycoproteins.

The use of Herpes Simplex Virus (HSV) in the treatment of tumour by extratumoural administration of HSV, and the use of HSV in treatment of tumour by combination therapy with a pharmaceutical wherein the HSV and/or pharmaceutical is administered at an extratumoural location, is disclosed.

Treatment using herpes simplex virus

Treatment of cancer using HSV mutant

An herpes simplex virus wherein the herpes simplex virus genome comprises nucleic acid encoding a nitroreductase (NTR) is disclosed. Disclosed herpes simplex viruses are indicated to be useful in the treatment of cancer which may involve gene directed enzyme prodrug therapy.

Mutant herpes simplex viruses comprising nucleic acid encoding a nitroreductase

A method is disclosed for identifying a substance capable of disrupting an interaction between (i) a herpes simplex virus (HSV) ICP34.5 polypeptide or a homologue thereof, or a derivative thereof, and (ii) proliferating cell nuclear antigen (PCNA) or a homologue thereof, or a derivative thereof, which method comprises: (a) providing an HSV ICP34.5 polypeptide or a homologue thereof, or a derivative thereof, as a first component; (b) providing PCNA, or a homologue thereof, or a derivative thereof, as a second component; (c) contacting the two components with a substance to be tested under conditions that would permit the two components to interact in the absence of the said substance; and (d) determining whether the said substance disrupts the interaction between the first and second components.

Methods for identifying cell cycle regulators

Novel Herpes simplex viruses and vaccines based on such novel HSV-1 strains are described. In particular, viruses having a deletion in the terminal portion of R are provided. The virus can be further modified to express heterologous antigens and also engineered to overproduce HSV Light particles. This is achieved by incorporating a ts mutation into the UL26 gene.

Herpes simplex virus-1 deletion variants and vaccines thereof

The present invention relates to a method for identifying a substance capable of disrupting an interaction between (i) a herpes simplex virus (HSV) ICP34.5 polypeptide or a homologue thereof, or a derivative thereof, and (ii) proliferating cell nuclear antigen (PCNA) or a homologue thereof, or a derivative thereof. The method comprises: (a) providing an HSV ICP34.5 polypeptide or a homologue thereof, or a derivative thereof, as a first component; (b) providing PCNA, or a homologue thereof, or a derivative thereof, as a second component; (c) contacting the two components with a substance to be tested under conditions that would permit the two components to interact in the absence of the substance; and (d) determining whether the substance disrupts the interaction between the first and second components.

Novel Herpes simplex viruses and vaccines based on such novel HSV-1 strains are described. In particular, viruses having a deletion in the terminal portion of R.sub.L are provided. The virus can be further modified to express heterologous antigens and also engineered to overproduce HSV Light particles. This is achieved by incorporating a ts mutation into the UL26 gene.

Growing community of inventors

Glasgow, United Kingdom

Susanne Moira Brown